Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) [Phase 1, Phase 2]
LIBRETTO-001 is a Phase 1/2 trial of selpercatinib in RET fusion–positive advanced solid tumors, including non-small cell lung cancer and me…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) [Phase 2]
Phase 2 MDT-BRIDGE trial evaluating neoadjuvant durvalumab with platinum-based chemotherapy in resectable or borderline resectable Stage IIB…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer [Phase 1]
Phase 1 clinical trial update evaluating osimertinib in combination with alisertib or sapanisertib for osimertinib-resistant EGFR-mutant sta…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) [Phase 2, Phase 3]
A Phase 2/3 clinical trial compares Izalontamab Brengitecan (BMS-986507) against platinum-pemetrexed for EGFR-mutated non-small cell lung ca…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases [Phase 2]
A Phase II study is evaluating the combination of pembrolizumab and lenvatinib in patients with triple-negative breast cancer, non-small cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer [NA]
This clinical trial update describes LiveWell, an adapted dialectical behavior therapy skills training protocol for patients living with met…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer [Phase 2]
A Phase II clinical study is investigating the probiotic LR607 in patients with non-small cell lung cancer who are candidates for radical su…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer [Phase 2]
This document provides an update on a Phase 2 platform trial evaluating immunomodulatory compounds for patients with non-small cell lung can…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets [Phase 3]
Phase 3 trial evaluating blood-brain barrier opening with Exablate Focused Ultrasound in combination with standard of care for brain metasta…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations [Phase 3]
A Phase 3 clinical trial evaluates the efficacy and safety of Firmonertinib versus investigator's choice of EGFR inhibitor as first-line the…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC [Phase 2]
Phase 2 trial evaluating Teclison's TATE in combination with pembrolizumab (MK3475) for metastatic colorectal cancer and non-small cell lung…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Patient Preference for Subcutaneous vs. Intravenous Immune Therapy [Phase 2]
Phase 2 clinical trial update on patient preference for subcutaneous versus intravenous immune therapy; the study is currently recruiting ac…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors [Phase 1]
Novartis' Phase 1 dose-finding trial of TNO155 in adults with advanced solid tumors has been terminated. No efficacy results are provided in…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of PF-07248144 in Advanced or Metastatic Solid Tumors [Phase 2]
Pfizer is conducting a Phase 2 study of PF-07248144 in locally advanced or metastatic ER+ HER2- breast cancer, locally advanced or metastati…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy [Phase 3]
A Phase III randomized trial evaluating Ceralasertib plus Durvalumab versus Docetaxel in advanced/metastatic non-small cell lung cancer afte…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer [Phase 2]
This Phase 2 clinical trial evaluates stereotactic body radiation therapy with or without nivolumab for patients with Stage I-IIA or recurre…
-
EMA approval · 2026-04-15EMA Authorised: Lorviqua (Lorlatinib) — Pfizer Europe MA EEIG
The EMA authorised Lorviqua (lorlatinib) for use in non-small cell lung cancer. The decision confirms EU approval of the product for this in…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer [Phase 3]
A Phase 3 study by ImmunityBio is evaluating N-803 plus tislelizumab and docetaxel versus docetaxel alone in advanced or metastatic non-smal…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation study of the investigational KRAS inhibitor KST-6051 in adults with KRAS-muta…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer [Phase 2]
This clinical trial update notes that a Phase 2 study of autologous LN-145 (lifileucel) for metastatic non-small cell lung cancer is current…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating nogapendekin alfa inbakicept for advanced non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: ITIL-306 in Advanced Solid Tumors [Phase 1]
A Phase 1 trial of ITIL-306 in advanced solid tumors sponsored by Instil Bio has been terminated.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating the safety and disease activity of combining Telisotuzumab Adizutecan with Osimertinib as first-line t…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]
A Phase 3 clinical trial (LUNG-2) evaluating whether Zongertinib (BI 1810631) improves outcomes in adults with advanced non-small cell lung …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer [Phase 1]
Open-label Phase 1 study evaluating BBO-8520 in adults with KRAS G12C-mutant non-small cell lung cancer; currently recruiting.